Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Proqr Therapeutics (NQ: PRQR ) 1.973 +0.113 (+6.05%) Streaming Delayed Price Updated: 12:45 PM EDT, Jul 31, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 51,216 Open 1.870 Bid (Size) 1.960 (8) Ask (Size) 1.990 (5) Prev. Close 1.860 Today's Range 1.856 - 1.973 52wk Range 1.110 - 3.290 Shares Outstanding 80,817,079 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News ProQR Announces Presentation on its Axiomer™ RNA Editing Technology at RNA Editing Summit June 18, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Announces First Quarter 2024 Operating and Financial Results May 09, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire Performance YTD -4.93% -4.93% 1 Month +19.55% +19.55% 3 Month +1.68% +1.68% 6 Month -8.68% -8.68% 1 Year +31.51% +31.51% More News Read More ProQR Announces Preclinical Proof of Concept Data for AX-0810 Axiomer™ RNA Editing Program Targeting NTCP for Cholestatic Diseases May 08, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire 4 Analysts Have This to Say About ProQR Therapeutics August 04, 2023 Via Benzinga Analyst Ratings for ProQR Therapeutics May 17, 2023 Via Benzinga ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024 April 23, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting April 22, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio April 19, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Announces Year End 2023 Operating and Financial Results March 13, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Announces Japanese Axiomer™ Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing February 15, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Highlights New Platform Data from Presentation on Axiomer™ RNA Editing Technology at Deaminet 2024 January 19, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session January 18, 2024 Via Benzinga ProQR and Rett Syndrome Research Trust Join Forces with Axiomer™ RNA Editing Collaboration January 05, 2024 From ProQR Therapeutics N.V. Via GlobeNewswire Why Airspan Networks Shares Are Trading Higher By Over 380%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session January 17, 2024 Via Benzinga ProQR Therapeutics Announces Transaction Completed for Théa to Acquire Sepofarsen and Ultevursen Ophthalmic Assets December 08, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire US Stocks Lower; Dow Falls Over 50 Points November 27, 2023 Via Benzinga Topics Stocks Exposures US Equities Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday November 08, 2023 Via Benzinga ProQR Announces Third Quarter 2023 Operating and Financial Results November 07, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Strengthens Leading Intellectual Property Estate for ADAR-mediated RNA Editing November 06, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Announces Participation in the Chardan 7th Annual Genetic Medicines Conference September 28, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Therapeutics Provides Update on Ophthalmic Assets September 27, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Announces Webcast of Presentation at the Upcoming HC Wainwright 25th Annual Global Investment Conference September 07, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Announces Second Quarter 2023 Operating and Financial Results August 03, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR Therapeutics and Laboratoires Théa Announce Agreement for Théa to Acquire ProQR’s Sepofarsen and Ultevursen Ophthalmic Assets August 01, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire ProQR to Present Data on its Axiomer® RNA Editing Technology at RNA Editing Summit July 06, 2023 From ProQR Therapeutics N.V. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
